2024
DOI: 10.1002/ijc.35193
|View full text |Cite
|
Sign up to set email alerts
|

Postmarketing adverse events of tamoxifen in male and female patients with breast cancer

Chengjie Ke,
Maohua Chen,
Li Lin
et al.

Abstract: Tamoxifen (TAM), a selective estrogen receptor (ER) modulator, has received approval for use in patients with breast cancer (BC) exhibiting positive ER expression. Given the widespread clinical use of TAM, a comprehensive real‐world study of its adverse events (AEs) is warranted. The database for analysis, sourced from the Food and Drug Administration Adverse Event Reporting System (FAERS), covers the period from the first quarter of 2014 to the third quarter of 2023. A disproportionality analysis was conducte… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
references
References 44 publications
0
0
0
Order By: Relevance